Diabetes is a malady that has been able to affect more than 29 million people in the Americas and over 86 million people have been diagnosed with blood sugar levels that have been high enough to be considered “pre-diabetic”. This has brought about the making of various medications and Onglyza is one of them as it has been able to help with the management of type 2 diabetes and is actually one of the first ever drugs of its kind to be approved by the FDA under the new safety standards concerning cardiovascular safety. It is intended to lower one’s glucose levels and other complications that may be associated with adult type 2 diabetes.
Nevertheless, despite having these standards, Onglyza has been linked to actually increase the risk of one developing heart failure, for some people it has even developed to death and patients that are harmed by the drug have been filing various lawsuits against the manufactures of the drugs. In the event that an individual by any chance or their loved one has been able to take the drug Onglyza and ended up experiencing heart failure, then one needs to understand that they are entitled to be compensated for the pain, the medical costs and the suffering that they have gone through.
Onglyza lawsuit information
The manufactures of the drug known as Onglyza, AstraZeneca, were able to win the approval of the FDA for their drug as a treatment for type 2 diabetes back in the year 2009. However, recently the drug has been associated with allegedly bringing about an increased rate of death due to heart failure. The drug has been classified and found to belong to a group of drugs that is known as Dipeptidyl Peptidase-4 (DPP-4) inhibitors. These drugs are known to affect the body’s production of glucose which is a form of managing diabetes.
As much as it brings about a high glycemic control, it also increases the chances of one developing heart failure as a result of using them. According to a clinical trial that was conducted, about 16,000 patients were able to link Onglyza to this risk. The patients who were given the drug had to be hospitalized as some were at a greater risk of developing heart failure as well as an increased risk for all causes of death.
Pharmaceutical companies that are associated with these drugs normally are expected to uphold their legal duty and warn the general masses of the many risks that may be associated with the use of their medical commodities. Any experienced pharmaceutical attorney is able to perform a no obligation, no cost evaluation of one’s case in order to help determine one’s legal options. One then will not be charged any fees except when they have been awarded a settlement or judgment. One needs to understand that the law normally is able to limit the amount of time that one has to file a claim. Hence, the sooner one is able to file the claim and make a case, the better for them to get good results out if the whole situation.
Some facts that have been associated with this specific the pharmaceutical drug may include the fact that the FDA normally expected that one be able to provide any evidence of drug safety. This is because there was need for them to see through the evidence presented that the type 2 diabetes drugs would not lead to one having an increase chance of them developing various cardiovascular related diseases. The drug was able to get the approval as a treatment for type 2 diabetes back in July 2009.
In the year 2013, October, SAVOR (Saxagliptin Assessment Of Vascular Outcomes Recorded in various patients with Diabetes Mellitus- Thrombolysis in Myocardial Infarction 53) showed that the individuals who had suffered from cardiovascular disease or any have been at risk of cardiovascular diseases were able to experience a higher risk of hospitalization due to heart failure.
The FDA at this point then had to review the drug and its safety to the public. At the end of the day they risk of one developing heart failure had been validated and been identified to increase the risk of death from all causes. This then prompted the FDA to put in a new rule where they would require that anew warning label be put on all products containing Saxagliptin, which is the active ingredient in Onglyza. However, in April 2016, the FDA was able to recommend that all health care professional stop any form of medications that contained Saxagliptin for any patients who developed heart failure.
Onglyza and heart failure
The drug that was manufactured by the pharmaceutical company known as AstraZeneca, is said to belong to a group of drugs that normally stimulate the pancreas into producing more insulin after one has eaten. According to the FDA upon reviewing their data, it was found that almost 30% of the people that received the treatments using Onglyza had an increase liability of being hospitalized due a higher risk of dying of the cause of heart failure or developing heart failure. Do you qualify for an Onglyza claim? Check here: https://www.nationalinjuryadvocates.com/onglyza-heart-failure-attorney/
Onglyza and heart failure symptoms.
Nevertheless, patients are advised to see a doctor in the vent that they end up suffering from the developing symptoms upon using the drug:
In conclusion, one need not suffer alone as there is legal help which one may easily seek out to help them deal with such issues. There are various things that clients have been able to sue the companies for and that include:
In the event that an individual has been diagnosed with heart failure or any other side effect that they believe may have been brought about by Onglyza, then one is advised to contact 800-631-5656 immediately and see if they qualify for the monetary compensation which they may be owed related to the litigation brought about by various individual.